UMDV:SW:SW-iShares US Medical Devices UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 5.976

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.64K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.05 (+0.37%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.15 (+0.73%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.25 (+0.94%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+31.00 (+0.61%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+15.80 (+1.00%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+42.00 (+2.07%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.38 (+0.50%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.18 (+0.16%)

USD 130,595.12B

ETFs Containing UMDV:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.27% 41% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.27% 40% F 43% F
Trailing 12 Months  
Capital Gain 9.13% 44% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.13% 43% F 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.20% 9% A- 12% F
Dividend Return -2.20% 9% A- 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.56% 36% F 43% F
Risk Adjusted Return -23.03% 14% F 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.